408 related articles for article (PubMed ID: 20334617)
1. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.
Phillips MA; Rathod PK
Infect Disord Drug Targets; 2010 Jun; 10(3):226-39. PubMed ID: 20334617
[TBL] [Abstract][Full Text] [Related]
2. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
[TBL] [Abstract][Full Text] [Related]
3. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
[TBL] [Abstract][Full Text] [Related]
4. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Gujjar R; El Mazouni F; White KL; White J; Creason S; Shackleford DM; Deng X; Charman WN; Bathurst I; Burrows J; Floyd DM; Matthews D; Buckner FS; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2011 Jun; 54(11):3935-49. PubMed ID: 21517059
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
[TBL] [Abstract][Full Text] [Related]
6. Recent advances on patents of
Gehlot P; Vyas VK
Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
[TBL] [Abstract][Full Text] [Related]
7. Identification of 3,4-Dihydro-2
Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
[No Abstract] [Full Text] [Related]
8. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK
J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
[TBL] [Abstract][Full Text] [Related]
10. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.
Gujjar R; Marwaha A; El Mazouni F; White J; White KL; Creason S; Shackleford DM; Baldwin J; Charman WN; Buckner FS; Charman S; Rathod PK; Phillips MA
J Med Chem; 2009 Apr; 52(7):1864-72. PubMed ID: 19296651
[TBL] [Abstract][Full Text] [Related]
11. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model.
Booker ML; Bastos CM; Kramer ML; Barker RH; Skerlj R; Sidhu AB; Deng X; Celatka C; Cortese JF; Guerrero Bravo JE; Crespo Llado KN; Serrano AE; Angulo-Barturen I; Jiménez-Díaz MB; Viera S; Garuti H; Wittlin S; Papastogiannidis P; Lin JW; Janse CJ; Khan SM; Duraisingh M; Coleman B; Goldsmith EJ; Phillips MA; Munoz B; Wirth DF; Klinger JD; Wiegand R; Sybertz E
J Biol Chem; 2010 Oct; 285(43):33054-33064. PubMed ID: 20702404
[TBL] [Abstract][Full Text] [Related]
13. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
Aher RB; Roy K
Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
[TBL] [Abstract][Full Text] [Related]
14. Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.
Xu M; Zhu J; Diao Y; Zhou H; Ren X; Sun D; Huang J; Han D; Zhao Z; Zhu L; Xu Y; Li H
J Med Chem; 2013 Oct; 56(20):7911-24. PubMed ID: 24073986
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
[TBL] [Abstract][Full Text] [Related]
16. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.
Hou X; Chen X; Zhang M; Yan A
SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561
[TBL] [Abstract][Full Text] [Related]
17. Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials.
Ojha PK; Roy K
Eur J Med Chem; 2010 Oct; 45(10):4645-56. PubMed ID: 20708304
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.
Pippione AC; Sainas S; Goyal P; Fritzson I; Cassiano GC; Giraudo A; Giorgis M; Tavella TA; Bagnati R; Rolando B; Caing-Carlsson R; Costa FTM; Andrade CH; Al-Karadaghi S; Boschi D; Friemann R; Lolli ML
Eur J Med Chem; 2019 Feb; 163():266-280. PubMed ID: 30529545
[TBL] [Abstract][Full Text] [Related]
19. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.
Ross LS; Gamo FJ; Lafuente-Monasterio MJ; Singh OM; Rowland P; Wiegand RC; Wirth DF
J Biol Chem; 2014 Jun; 289(26):17980-95. PubMed ID: 24782313
[TBL] [Abstract][Full Text] [Related]
20. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
